Carvedilol tablets compared with endoscopic banding treatment in preventing rebleeding from oesophgaeal varices
Not Applicable
Completed
- Conditions
- Variceal rebleeding in cirrhotic patientsDigestive SystemOther diseases of liver
- Registration Number
- ISRCTN69643049
- Lead Sponsor
- Greater Glasgow & Clyde (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 152
Inclusion Criteria
1. Male or female aged =18 and <75yrs
2. Endoscopic diagnosis of oesophageal variceal bleeding
3. Cirrhosis (based on previous liver biopsy or clinical, biochemical and ultrasonographic findings)
Exclusion Criteria
1. Age <18 or >75 years
2. Advanced malignancy or another condition associated with a life expectancy of < 6/12 months
3. Previous transjugular intrahepatic portosystemic shunt (TIPS) or porto-caval shunt surgery
4. Portal vein thrombosis
5. Obstructive airways disease
6. Severe peripheral vascular disease
7. Heart block
8. Severe heart failure
9. Pregnancy
10. Type I diabetes mellitus
11. Gastric variceal bleed
12. Treatment with beta blockers or alpha blockers within 4 weeks of index bleed
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Variceal rebleeding is monitored when it occurs during follow-up. Patients will be followed up until 6 months after the last patient is randomised.
- Secondary Outcome Measures
Name Time Method 1. Mortality<br>2. Any upper gastointestinal bleeding is monitored when it occurs during follow-up